Research interests
My research focuses on bacterial evolution across environments. During my PhD, I used comparative genomics, phylogenetic analysis, and environmental metagenomics to study how bacteria successively colonized the terrestrial environment (The ISME Journal, 2014). This work sparked my continued interest in understanding how these microorganisms, after colonizing land, established extensive interactions with various hosts, including humans.
Our laboratory is now dedicated to address: 1) what roles of this 'second genome' play in human health and diseases and what are the factors driving their changes? 2) what are the mechanisms by which the gut microbiota influences the spectrum of cardiometabolic diseases? By employing a multidisciplinary toolkit—including fecal microbiota transplantation in germ-free mice, in vitro gut microbial simulation, and integrated multi-omics analyses of clinical cohorts—we seeks to decipher the mechanistic role of gut microbes in the pathogenesis, development, and prevention of diverse cardiometabolic disorders.
Our past findings include:
(1) Gut dysbiosis as an early event in T2D, where microbial imbalance precedes and predicts disease risk, offering a tool for precision prevention (Cell Metabolism, 2020; EMBO Molecular Medicine 2023).
(2) Modulation of drug efficacy by the gut microbiota, revealing that microbes influence glucose- and lipid-lowering drug effectiveness, thus informing personalized therapies (Nature Medicine, 2017; Nature Communications 2023).
(3) Microbiota-guided precision nutrition, demonstrating that a specific high-protein diet reduces hepatic steatosis by enhancing bacterial folate production, supporting probiotic and functional food applications (Cell Metabolism, 2018).
(4) Analysis of T2D-associated metabolites revealed distinct but complementary roles of diet and exercise in modulating host metabolism, suggesting that optimal outcomes require integrated multi-modal clinical strategies (Nature Medicine, 2025).
Education and Work Experience
2021-present, Fudan Microbiome Center, Human Phenome Institute, Fudan University;
2021-present, Huashan Hospital affiliated to Fudan University;
2015-2020, Sahlgrenska university hospital, University of Gothenburg, Sweden;
2012-2014, Beijing Institute of Genomics, Chinese Academy of Sciences;
2007-2012, James Watson Institute of Genome Sciences, Zhejiang University;
2002-2006, Department of Life Sciences, Shandong University of Technology;
吴浩，复旦大学人类表型组研究院、复旦微生物组中心，青年研究员，博士生导师；复旦大学附属华山医院代谢与减重外科双聘专家；入选上海市浦江人才、青年领军人才；国家海外高层次人才（青年）。
兼任生物物理学会肠道菌群分会副会长、代谢生物学分会青年委员、表型组学分会委员；生物化学与分子生物学会代谢专业委员会委员；微生物学会微生物组专业委员会委员；人体健康科技促进会肠道微生态与肠菌移植专业委员会委员；中华预防医学会微生态分会委员。
主要研究肠道菌与饮食互作对肥胖、非酒精性脂肪肝及糖尿病等代谢性疾病发生发展及防治的影响，以第一或通讯作者身份在 Nature Medicine （2017, 2025），Cell Metabolism （2018， 2020），Cell Host & Microbe, Nature Communications，The ISME J 等杂志发表20多篇学术论文。